1. DOP47 Sustained remission in patients with moderate to severe ulcerative colitis: Results from the Phase 3 UNIFI maintenance study. (25th January 2019) Authors: Van Assche, G; Targan, S R; Baker, T; O'Brien, C D; Zhang, H; Johanns, J; Szapary, P; Marano, C; Leong, R W; Rowbotham, D; Hisamatsu, T; Danese, S; Sands, B E; Peyrin-Biroulet, L Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S054 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. DOP54 Efficacy and safety of ustekinumab through Week 16 in patients with moderate-to-severe ulcerative colitis randomised to ustekinumab: results from the UNIFI induction trial. (25th January 2019) Authors: Danese, S; Sands, B E; O'Brien, C D; Zhang, H; Johanns, J; Sloan, S; Izanec, J; Szapary, P; Marano, C; Leong, R W; Rowbotham, D; Targan, S R; Van Assche, G Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S061 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P312 Efficacy in biologic failure and non-biologic-failure populations in a Phase 3 study of ustekinumab in moderate–severe ulcerative colitis: UNIFI. (25th January 2019) Authors: Sands, B E; Peyrin-Biroulet, L; Marano, C; O'Brien, C D; Zhang, H; Johanns, J; Szapary, P; Rowbotham, D; Leong, R W; Arasaradnam, R P; Danese, S; Van Assche, G; Targan, S; Sandborn, W J Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S256 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗